120 related articles for article (PubMed ID: 38110004)
1. Enhancing HCC recurrence prediction after liver transplantation: From DCP plus AFP-L3 model to GALAD score.
Hahn M; Herber A; Berg T; Seehofer D; van Bömmel F
J Hepatol; 2024 Jun; 80(6):e271-e272. PubMed ID: 38110004
[No Abstract] [Full Text] [Related]
2. Reply to: "Enhancing HCC recurrence prediction after liver transplantation: From DCP plus AFP-L3 model to GALAD score".
Norman JS; Mehta N
J Hepatol; 2024 Jun; 80(6):e273-e274. PubMed ID: 38346579
[No Abstract] [Full Text] [Related]
3. GALAD score as a prognostic model for recurrence of hepatocellular carcinoma after local ablation.
Qiao W; Li J; Xiong Y; Zheng J; Jin R; Hu C
J Cancer Res Clin Oncol; 2024 May; 150(5):241. PubMed ID: 38713414
[TBL] [Abstract][Full Text] [Related]
4. Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation.
Chaiteerakij R; Zhang X; Addissie BD; Mohamed EA; Harmsen WS; Theobald PJ; Peters BE; Balsanek JG; Ward MM; Giama NH; Moser CD; Oseini AM; Umeda N; Venkatesh S; Harnois DM; Charlton MR; Yamada H; Satomura S; Algeciras-Schimnich A; Snyder MR; Therneau TM; Roberts LR
Liver Transpl; 2015 May; 21(5):599-606. PubMed ID: 25789635
[TBL] [Abstract][Full Text] [Related]
5. AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation.
Norman JS; Li PJ; Kotwani P; Shui AM; Yao F; Mehta N
J Hepatol; 2023 Dec; 79(6):1469-1477. PubMed ID: 37683735
[TBL] [Abstract][Full Text] [Related]
6. The ratio of preoperative alpha-fetoprotein level to total tumor volume as a prognostic factor of hepatocellular carcinoma after liver transplantation.
Jiang T; Zhang XS; Pan F; Lyu SC; Wang J; Huang MX; He Q; Lang R
Medicine (Baltimore); 2021 Jul; 100(26):e26487. PubMed ID: 34190174
[TBL] [Abstract][Full Text] [Related]
7. Clinical Significance of Preoperative Hepatocellular Carcinoma With High
Yamao T; Yamashita YI; Imai K; Umezaki N; Tsukamoto M; Kitano Y; Arima K; Miyata T; Nakagawa S; Okabe H; Hayashi H; Chikamoto A; Ishiko T; Baba H
Anticancer Res; 2019 Feb; 39(2):883-889. PubMed ID: 30711971
[TBL] [Abstract][Full Text] [Related]
8. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
[TBL] [Abstract][Full Text] [Related]
9. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma.
Best J; Bilgi H; Heider D; Schotten C; Manka P; Bedreli S; Gorray M; Ertle J; van Grunsven LA; Dechêne A
Z Gastroenterol; 2016 Dec; 54(12):1296-1305. PubMed ID: 27936479
[No Abstract] [Full Text] [Related]
10. Changes in highly sensitive alpha-fetoprotein for the prediction of the outcome in patients with hepatocellular carcinoma after hepatectomy.
Toyoda H; Kumada T; Tada T; Ito T; Maeda A; Kaneoka Y; Kagebayashi C; Satomura S
Cancer Med; 2014 Jun; 3(3):643-51. PubMed ID: 24591342
[TBL] [Abstract][Full Text] [Related]
11. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
Giard JM; Mehta N; Dodge JL; Roberts JP; Yao FY
Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
[TBL] [Abstract][Full Text] [Related]
12. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
13. Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma.
Shindoh J; Sugawara Y; Nagata R; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Tanaka T; Kokudo N
Transpl Int; 2014 Apr; 27(4):391-8. PubMed ID: 24472068
[TBL] [Abstract][Full Text] [Related]
14. The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States.
Tayob N; Kanwal F; Alsarraj A; Hernaez R; El-Serag HB
Clin Gastroenterol Hepatol; 2023 Feb; 21(2):415-423.e4. PubMed ID: 35124267
[TBL] [Abstract][Full Text] [Related]
15. Chinese expert consensus statement on the clinical application of AFP/AFP-L3%/DCP using GALAD and GALAD-like algorithm in HCC.
Huang C; Xiao X; Zhou L; Chen F; Wang J; Hu X; Gao C;
J Clin Lab Anal; 2023 Dec; 37(23-24):e24990. PubMed ID: 38063322
[TBL] [Abstract][Full Text] [Related]
16. Risk factors of hepatocellular carcinoma recurrence after liver transplantation: accuracy of the alpha-fetoprotein model in a single-center experience.
Varona MA; Soriano A; Aguirre-Jaime A; Garrido S; Oton E; Diaz D; Portero J; Bravo P; Barrera MA; Perera A
Transplant Proc; 2015; 47(1):84-9. PubMed ID: 25645778
[TBL] [Abstract][Full Text] [Related]
17. The Importance of AFP in Liver Transplantation for HCC.
Özdemir F; Baskiran A
J Gastrointest Cancer; 2020 Dec; 51(4):1127-1132. PubMed ID: 32845425
[TBL] [Abstract][Full Text] [Related]
18. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis.
Best J; Bechmann LP; Sowa JP; Sydor S; Dechêne A; Pflanz K; Bedreli S; Schotten C; Geier A; Berg T; Fischer J; Vogel A; Bantel H; Weinmann A; Schattenberg JM; Huber Y; Wege H; von Felden J; Schulze K; Bettinger D; Thimme R; Sinner F; Schütte K; Weiss KH; Toyoda H; Yasuda S; Kumada T; Berhane S; Wichert M; Heider D; Gerken G; Johnson P; Canbay A
Clin Gastroenterol Hepatol; 2020 Mar; 18(3):728-735.e4. PubMed ID: 31712073
[TBL] [Abstract][Full Text] [Related]
19. Alpha-fetoprotein Level Predicts Recurrence After Transplantation in Hepatocellular Carcinoma.
Schraiber LDS; de Mattos AA; Zanotelli ML; Cantisani GPC; Brandão ABM; Marroni CA; Kiss G; Ernani L; Marcon PDS
Medicine (Baltimore); 2016 Jan; 95(3):e2478. PubMed ID: 26817881
[TBL] [Abstract][Full Text] [Related]
20. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma.
Mazzaferro V; Sposito C; Zhou J; Pinna AD; De Carlis L; Fan J; Cescon M; Di Sandro S; Yi-Feng H; Lauterio A; Bongini M; Cucchetti A
Gastroenterology; 2018 Jan; 154(1):128-139. PubMed ID: 28989060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
